ROS1 Expression in Invasive Ductal Carcinoma of the Breast Related to Proliferation Activity

Eom, Minseob; Lkhagvadorj, Sayamaa; Oh, Sung Soo; Han, Airi; Park, Kwang Hwa

doi:10.3349/ymj.2013.54.3.650

Cited by 12 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is in agreement with the results of a previous study concerning gastric carcinomas (11), but contradict with a study that examined breast carcinomas, which revealed improved survival with increasing ROS1 expression (25), and with a study that investigated cases of NSCLC, which demonstrated poorer survival rates with increasing ROS1 expression (11). Previous studies that analyzed other receptor tyrosine kinases, including c-MET, VEGF and Akt, revealed that these receptors are involved in the development and prognosis of OSCC (15)(16)(17)(18).…”

Section: Discussionsupporting

confidence: 82%

“…In addition, the staining pattern of ROS1 has been identified to differ in different types of tumors. Cytoplasmic staining patterns were observed in human non-small cell lung cancers (NSCLCs), gastric adenocarcinomas, glioblastomas, HCC78 cells and U118MG cells (11,24); membrane and cytoplasmic patterns were evident in breast carcinomas, and membrane patterns were apparent in hepatocarcinomas (25). The factors responsible for these different localization patterns are yet to be elucidated (24).…”

Section: Discussionmentioning

confidence: 99%

“…In addition, ROS1 expression has been shown to be associated with the differentiation of tumors, including gastric adenocarcinomas (11), astrocytomas (26), and invasive breast carcinomas (25). Further studies are required in order to address the function of ROS1 signaling in the context of cell differentiation and transformation.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma

et al. 2015

View full text Add to dashboard Cite

Abstract. The c-ros oncogene 1 receptor tyrosine kinase (ROS1) gene encodes a proto-oncogenic protein that has been demonstrated to be involved in the pathogenesis of several types of cancer. The present study aimed to analyze the expression of ROS1 in human oral squamous cell carcinomas (OSCCs), and investigate the association between its expression and the clinicopathological parameters of patients with OSCC. Paraffin-embedded OSCC tissues from 31 patients were obtained and the expression of ROS1 was analyzed by immunohistochemistry. The cellular location of ROS1 was determined by immunofluorescence in human oral cancer CAL-27 cells. The association of clinicopathological characteristics and survival rates with ROS1 expression were assessed. The results revealed that ROS1 was exclusively localized in the cytoplasm of the OSCC tissues (24/30, 80.0%), and in the cytoplasm of adjacent dysplastic epithelial tissues (2/15, 13.3%) (P<0.001). The moderate to strong expression of ROS1 in the cytoplasm was higher in OSCC tissues than in the normal epithelial tissues adjacent to the tumor (67.7 vs. 0%, P=0.001). The results of the Kaplan-Meier analysis and multivariate Cox regression analysis indicated that there was no association between the 5-year survival rate of patients and the cytoplasmic (P=0.28 and P=0.60, respectively) or nuclear expression (P=0.90 and P=0.31, respectively) of ROS1. These results suggest that the cytoplasmic expression level of ROS1 may be associated with the development of OSCC.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…ROS1 mutations associated with acquired resistance to ROS1 TKI have been reported, and several next-generation ROS1 TKIs were shown to overcome crizotinib resistance (57). Although there is currently no report of ROS1 gene rearrangement in breast cancer, a study that examined gene and protein expression of ROS1 in invasive ductal carcinoma (IDC) of the breast indicated that ROS1 expression is related to cell proliferation and reported a potential association between higher ROS1 expression and better prognosis (192, 193). More studies are needed to determine whether current ROS1 inhibitors may be useful as treatment for IDC in the future.…”

Section: 3 Other Rtksmentioning

confidence: 99%

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Hsu

Hung

2016

Cancer Metastasis Rev

291

185

View full text Add to dashboard Cite

Breast cancer affects approximately 1 in 8 women, and it is estimated that over 246,660 women in the United States will be diagnosed with breast cancer in 2016. Breast cancer mortality has decline over the last two decades due to early detection and improved treatment. Over the last few years, there is mounting evidence to demonstrate the prominent role of receptor tyrosine kinases (RTKs) in tumor initiation and progression, and targeted therapies against the RTKs have been developed, evaluated in clinical trials, and approved for many cancer types, including breast cancer. However, not all breast cancers are the same as evidenced by the multiple subtypes of the disease, with some more aggressive than others, showing differential treatment response to different types of drugs. Moreover, in addition to canonical signaling from the cell surface, many RTKs can be trafficked to various subcellular compartments, such as the multivesicular body and nucleus, where they carry out critical cellular functions, such as cell proliferation, DNA replication and repair, and therapeutic resistance. In this review, we provide a brief summary on the role of a selected number of RTKs in breast cancer and describe some mechanisms of resistance.

show abstract

“…Eom et al recently examined the expression of ROS1 protein and gene in invasive ductal carcinoma (IDC) of the breast 33. Tumour samples from 203 patients were included to investigate the expression of ROS1 protein by IHC and ROS1 gene by RT-PCR.…”

Section: Ros1 and Other Tumoursmentioning

confidence: 99%

ROS1-1

Pal

Khan

2017

J Clin Pathol

View full text Add to dashboard Cite

ROS1 is a receptor tyrosine kinase that has recently been shown to undergo gene rearrangements in~1%-2% of non-small cell lung carcinoma (NSCLC) and in a variety of other tumours including cholangiocarcinoma, gastric carcinoma, colorectal carcinoma and in spitzoid neoplasms, glioblastoma and inflammatory myofibroblastic tumours. The ROS1 gene fusion undergoes constitutive activation, regulates cellular proliferation and is implicated in carcinogenesis. ROS1 fusions can be detected by fluorescence in situ hybridisation, real-time PCR, sequencing-based techniques and immunohistochemistry-based methods in clinical laboratories. The small molecule tyrosine kinase inhibitor, crizotinib has been shown to be an effective inhibitor of ROS1 and has received Food and Drug Administration approval for treatment of advanced NSCLC. The current review is an update on the clinical findings and detection methods of ROS1 in clinical laboratories in NSCLC and other tumours.

show abstract

ROS1 Expression in Invasive Ductal Carcinoma of the Breast Related to Proliferation Activity

Cited by 12 publications

References 23 publications

Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma

Cytoplasmic c-ros oncogene 1 receptor tyrosine kinase expression may be associated with the development of human oral squamous cell carcinoma

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

ROS1-1

Contact Info

Product

Resources

About